Pomelo Care vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Pomelo Care hit $1.7B unicorn ($92M Series C, Jan 2026) covering ~7% of US births (25M+ lives) with peer-reviewed results: 37% fewer preterm births, 46% lower ER utilization.
About
Pomelo Care is a New York-based virtual maternity and women's health company that raised $92 million in Series C funding in January 2026, reaching a $1.7 billion unicorn valuation. The round was led by Stripes with participation from Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, and SV Angel. Founded in 2021, Pomelo now supports nearly 7 percent of all U.S. births.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.